Literature DB >> 10576656

Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor.

X X Tian1, J Y Chan, J C Pang, J Chen, J H He, T S To, S F Leung, H K Ng.   

Abstract

Gene amplification and enhanced expression of the epidermal growth factor receptor (EGFR) represent the major molecular genetic alteration in glioblastomas and it may play an essential role in cell growth and in the carcinogenic process. On the other hand, the nuclear suppressor proteins PML and p53 are also known to play critical roles in cancer development and in suppressing cell growth. Here we report that, in glioblastoma cells with defective EGFR function, the expressions of both promyelocytic leukaemia (PML) and p53 were altered. Cells that were transfected with the antisense-cDNA of EGFR were found to have more cells in G1 and fewer cells in S phase. In addition, the transfected cells were found to be non-responsive to EGF-induced cell growth. Interestingly, the expression of the suppressors p53 and PML were found to be significantly increased by immunohistochemical assay in the antisense-EGFR cells. Moreover, the PML expression in many of the cells was converted from the nuclear dot pattern into fine-granulated staining pattern. In contrast, the expressions of other cell cycle regulated genes and proto-oncogene, including the cyclin-dependent kinase 4 (cdk4), retinoblastoma, p16INK4a and p21H-ras, were not altered. These data indicate that there are specific inductions of PML and p53 proteins which may account for the increase in G1 and growth arrest in antisense-EGFR treated cells. It also indicates that the EGF, p53 and PML transduction pathways were linked and they may constitute an integral part of an altered growth regulatory programme. The interactions and cross-talks of these critical molecules may be very important in regulating cell growth, differentiation and cellular response to treatment in glioblastomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10576656      PMCID: PMC2362944          DOI: 10.1038/sj.bjc.6690798

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

Review 1.  Growth factor receptor tyrosine kinases.

Authors:  Y Yarden; A Ullrich
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

2.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.

Authors:  J P Morgenstern; H Land
Journal:  Nucleic Acids Res       Date:  1990-06-25       Impact factor: 16.971

Review 3.  Cell cycle control and cancer.

Authors:  L H Hartwell; M B Kastan
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

4.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

5.  Altered expression of the growth and transformation suppressor PML gene in human hepatocellular carcinomas and in hepatitis tissues.

Authors:  J Y Chan; W Chin; C T Liew; K S Chang; P J Johnson
Journal:  Eur J Cancer       Date:  1998-06       Impact factor: 9.162

6.  Wild-type human p53 activates the human epidermal growth factor receptor promoter.

Authors:  S P Deb; R M Muñoz; D R Brown; M A Subler; S Deb
Journal:  Oncogene       Date:  1994-05       Impact factor: 9.867

7.  PML, a growth suppressor disrupted in acute promyelocytic leukemia.

Authors:  Z M Mu; K V Chin; J H Liu; G Lozano; K S Chang
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

8.  EGF-R antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line.

Authors:  M C Moroni; M C Willingham; L Beguinot
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157

9.  PML nuclear bodies are general targets for inflammation and cell proliferation.

Authors:  B Terris; V Baldin; S Dubois; C Degott; J F Flejou; D Hénin; A Dejean
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

10.  HSV-1 IE protein Vmw110 causes redistribution of PML.

Authors:  R D Everett; G G Maul
Journal:  EMBO J       Date:  1994-11-01       Impact factor: 11.598

View more
  5 in total

1.  Ginsenoside Rh2 inhibits growth of glioblastoma multiforme through mTor.

Authors:  Shaoyi Li; Wenchang Guo; Yun Gao; Yunhui Liu
Journal:  Tumour Biol       Date:  2014-11-28

2.  Inhibition of FoxO1 nuclear exclusion prevents metastasis of glioblastoma.

Authors:  Jin Chen; Qin Huang; Feng Wang
Journal:  Tumour Biol       Date:  2014-04-27

3.  EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2.

Authors:  Shaoyi Li; Yun Gao; Weining Ma; Wenchang Guo; Gang Zhou; Tianci Cheng; Yunhui Liu
Journal:  Tumour Biol       Date:  2014-02-21

4.  Antisense epidermal growth factor receptor RNA transfection in human glioblastoma cells down-regulates telomerase activity and telomere length.

Authors:  X-X Tian; J C S Pang; J Zheng; J Chen; S S T To; H-K Ng
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

5.  Promyelocytic leukemia (PML) protein plays important roles in regulating cell adhesion, morphology, proliferation and migration.

Authors:  Mei Kuen Tang; Yong Jia Liang; John Yeuk Hon Chan; Sing Wan Wong; Elve Chen; Yao Yao; Jingyi Gan; Lihai Xiao; Hin Cheung Leung; Hsiang Fu Kung; Hua Wang; Kenneth Ka Ho Lee
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.